| Day 1, Thursday, May 14th | |
|---|---|
| 08:00–09:15 | Re-defining frontline myeloma therapy: The emerging role of BCMA-directed strategies in newly diagnosis multiple myeloma Pre-COMy CME Symposium |
| 09:15–09:25 | COMy 2026 kick-off: Welcome by the Congress Chairs |
| 09:25–10:40 | Session 1: Advances in biology |
| Moderators: Hervé Avet-Loiseau, France; Rafael Fonseca, USA | |
| 09:25–09:40 | Genomics: Francesco Maura, USA |
| 09:40–09:55 | Microenvironment: Madhav Dhodapkar, USA |
| 09:55–10:10 | Role of immune microenvironment in myeloma: Paola Neri, Canada |
| 10:10–10:25 | Liquid biopsies: Joaquín Martínez López, Spain |
| 10:25–10:40 | Discussion: All session faculty and Gareth Morgan, USA + Mehmet Samur, USA |
| 10:40–11:00 | Coffee Break |
| 11:00–12:15 | Session 2: New response criteria |
| Moderators: Rafat Abonour, USA; Heinz Ludwig, Austria | |
| 11:00–11:15 | Historical perspective: Joan Bladé, Spain |
| 11:15–11:30 | Summary of new response criteria: Shaji Kumar, USA |
| 11:30–11:45 | Role of MRD: Susan Bal, USA |
| 11:45–12:00 | Role of SFL chains and role of urine: Kwee Yong, UK |
| 12:00–12:15 | Mass spectrometry: Noemi Puig, Spain |
| 12:15–13:30 | Improving the journey: Patient-focused advances with CD38 mAb quadruplet therapy Industry-supported Symposium |
| 13:30–14:00 | Lunch Break |
| 14:00–15:15 | Industry-supported Symposium |
| 15:15–16:30 | Session 3: Mechanisms of resistance |
| Moderators: Faith Davies, USA; Marc Raab, Germany | |
| 15:15–15:30 | Resistance to CAR T: Carlos Fernández de Larrea, Spain |
| 15:30–15:45 | Résistance to bispecifics: Hermann Einsele, Germany |
| 15:45–16:00 | Resistance to ImiDs: Keith Stewart, Canada |
| 16:00–16:15 | Overcoming resistance: Nizar Bahlis, Canada |
| 16:15–16:30 | Discussion: All session faculty and Malin Hultcrantz, USA + Michael O’Dwyer, Ireland |
| 16:30–16:50 | Coffee Break |
| 16:50–18:05 | Session 4: Plenary lectures I |
| Moderators: Wee Joo Chng, Singapore; Noopur Raje, USA | |
| 16:50–17:05 | Smoldering multiple myeloma: María-Victoria Mateos, Spain |
| 17:05–17:20 | Waldenstrom Disease: Steven Treon, USA |
| 17:20–17:35 | Amyloidosis: Suzanne Lentzsch, USA |
| 17:35–17:50 | Discussion: All session faculty and Rahul Banerjee, USA + Robert Orlowski, USA |
| 17:50-19:00 | Session 5: How to manage high risk disease |
| Moderators: Meral Beksaç, Turkey; Vania Hungria, Brazil | |
| 17:50-18:05 | New classification: Jill Corre, France |
| 18:05-18:20 | Extra-medullary disease: Saad Usmani, USA |
| 18:20-18:35 | Plasma cell leukemia: Cyrille Touzeau, France |
| 18:35-18:50 | Functional high-risk: Martin Kaiser, UK |
| 18:50-19:00 | Discussion: All session faculty and Luciano Costa, USA + and Rakesh Popat, UK |
| Day 2, Friday, May 15th | |
|---|---|
| 07:00–08:00 | Session 6: Webinar showcase from IACH I |
| Video Session | |
| 08:00–09:15 | Clinical Application of clonoSEQ Testing in multiple myeloma Industry-supported Symposium |
| 09:15–10:30 | Medical Crossfire: Turning Therapuetic Innovation Into Practice-Personalizing Care in Multiple Myeloma CME Symposium |
| 10:30–10:50 | Coffee Break |
| 10:50–12:05 | Session 7: Cure: hope, hype or reality? |
| Moderators: Irene Ghobrial, USA; Jean-Luc Harousseau, France | |
| 10:50–11:05 | My definition of cure: Sagar Lonial, USA |
| 11:05–11:20 | My definition of cure: Vincent Rajkumar, USA |
| 11:20–11:35 | My definition of cure: Jesús San Miguel, Spain |
| 11:35–11:50 | Precursor disease and cure: Irene Ghobrial, USA |
| 11:50–12:05 | Discussion: All session faculty and Catarina Geraldes, Portugal |
| 12:05–13:20 | The red thread of innovation: emerging data and strategies in RRMM treatment Industry-supported Symposium |
| 13:20–13:50 | Lunch Break |
| 13:30-13:45 | Session 8: Webinar showcase from IACH II |
| Video Session during the Lunch Break | |
| 13:50–14:25 | Session 9: COMy Awards and lecture series |
| Chairs: Mohamad Mohty, France; María-Victoria Mateos, Spain; Arnon Nagler, Israel | |
| Awards Presentations Jean-Luc Harousseau Award Multiple Myeloma Pioneers Award Women in Multiple Myeloma Achievement Award | |
| 14:25–15:40 | Debating the future of RRMM: What is best for our patients? Industry-supported Symposium |
| 15:40–16:40 | Session 10: IMS Session – Multiple myeloma: is cure on the horizon? |
| Chairs: Philippe Moreau, France; Nikhil Moreau, USA | |
| 16:40-17:55 | Unmet Needs in RRMM: Evolving BsAb Therapy From Inpatient to Outpatient Settings Industry-supported Symposium |
| 17:55-18:15 | Coffee Break |
| 18:15–19:45 | Session 11: State-of-the-art management |
| Moderators: Thierry Facon, France; Francesca Gay, Italy | |
| 18:15–18:35 | Elderly patients: Salomon Manier, France |
| 18:35–18:55 | TE patients: Aurore Perrot, France |
| 18:55–19:15 | Bone disease: Evangelos Terpos, Greece |
| 19:15-19:30 | Thrombosis in myeloma: Uriel Suárez, Spain |
| 19:30-19:45 | Discussion: All session faculty and Faisal Basheer, UK + Holly Lee, Canada |
| 19:45–20:15 | Session 12: What’s new at aIACH: educational tools for your clinical day-to-day |
| Day 3, Saturday, May 16th | |
|---|---|
| 07:00–08:00 | Session 13: Clinical cases |
| Chairs: Claudio Cerchione, Italy; Nour Moukalled, Lebanon | |
| 07:00-07:20 | Case discussion 1: Arthur Bobin, France |
| 07:20-07:40 | Case discussion 2: thrombosis in myeloma: Emilie Chalayer, France |
| 07:40-08:00 | Dicussion: All session faculty and Thomas Chalopin, France + Uriel Suárez, Spain |
| 08:00–09:15 | MRD 2.0 : Minimal Invasion, Maximum Insight Industry-supported Symposium |
| 09:15–10:30 | Redefining Myeloma Care: An Expert Roundtable on the Potential of Novel Strategies Across the Disease Spectrum CME Symposium |
| 10:30–10:50 | Coffee Break |
| 10:50–12:00 | Session 14: The hard-to-treat-patients |
| Moderators: Chandramouli Nagarajan, Singapore; Joshua Richter, USA | |
| 10:50–11:10 | The case for peptide conjugates: Elena Zamagni, Italy |
| 11:10–11:30 | NDMM under dialysis: Florent Malard, France |
| 11:30-12:00 | Discussion: All session faculty and Doris Hansen, USA + Xavier Leleu, France + Hira Mian, Canada |
| 12:00–13:15 | The Evolving Role of ADC-Based BCMA Targeting in RRMM: Evidence-Led Practicalities of Early Intervention Industry-supported Symposium |
| 13:15–13:45 | Lunch Break |
| 13:25-13:40 | Session 15: Webinar showcase from IACH III |
| Video Session | |
| 13:45–14:50 | Session 16: COMy debates |
| Moderators: Michel Delforge, Belgium; Thomas Martin, USA | |
| 13:45-13:55 | 1st relapse, the case for CAR T cells: Luciano Costa, USA |
| 13:55-14:05 | 1st relapse, the case for Ab drug conjugates: Meletios (Thanos) Dimopoulos, Greece |
| 14:05-14:15 | Discussion: Debate faculty and Roman Hajek, Czech Republic + Andrzej Jakubowiak, USA |
| 14:15-14:25 | Doublet maintenance: Paul Richardson, USA |
| 14:25-14:35 | Single agent maintenance: Pieter Sonneveld, Netherlands |
| 14:35-14:50 | Discussion: Debate faculty and Hartmut Goldschmidt, Germany + Andrew Spencer, Australia |
| 14:50–16:05 | Advancing RRMM Care With T-cell Redirecting Therapies: Current Landscape and Future Directions Industry-supported Symposium |
| 16:05–17:20 | Beyond Head-to-Head Trials: Answering Real Myeloma Questions – What Matching-Adjusted Indirect Comparisons (MAICs) Show and What They Don’t Industry-supported Symposium |
| 17:20–17:30 | Coffee Break |
| 17:30–19:30 | Session 17: Plenary lectures II |
| Moderators: Jesús Berdeja, USA; Joy Ho, Australia | |
| 17:30-18:00 | 35 years of myeloma trials: Philippe Moreau, France |
| 18:00-18:30 | Genomics guiding therapy: Nikhil Munshi, USA |
| 18:30-19:00 | The future of multiple myeloma therapy: Kenneth Anderson, USA |
| 19:00-19:30 | Discussion: All session faculty and Mohamad Mohty, France + Arnon Nagler, Israel |
| 19:30–20:00 | Session 18: COMy in-person conclusions |
| Day 4, Sunday, May 17th – ONLINE ONLY | |
|---|---|
| 10:00-11:05 | Multiple Myeloma Communications I |
| Moderators: Mohamad Mohty, France; María-Victoria Mateos, Spain; Arnon Nagler, Israel | |
| 10:00-10:10 | Daratumumab (Dara) Monotherapy vs. Active Monitoring (ActMon) in Patients with High-Risk Smoldering Myeloma (SMM): AQUILA Outcomes based on Mayo 2018/IMWG 2020 Risk Stratification, IMWG 2020 plus Cytogenetic Criteria, and Age: Philippe Moreau, France |
| 10:10-10:20 | ARLOCABTAGENE AUTOLEUCEL (ARLO-CEL) IN PATIENTS WITH HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL ANALYSIS FROM THE PHASE 1 STUDY: Susan Bal, USA |
| 10:20-10:30 | Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel (cilta-cel): phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma: Xavier Leleu, France |
| 10:30-10:40 | BELANTAMAB MAFODOTIN, BORTEZOMIB, AND DEXAMETHASONE (BVd) VS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASOME (DVd) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LONG-TERM RESPONDER ANALYSIS OF THE PHASE 3 DREAMM-7 TRIAL: Vania Hungria, Braziil |
| 10:40-10:50 | SUBGROUP ANALYSIS OF DREAMM-7 AND DREAMM-8: OUTCOMES WITH BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITH FUNCTIONAL HIGH-RISK (FHR) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): María-Victoria Matoes, Spain |
| 10:50-11:05 | Discussion |
| 11:05-11:15 | Break |
| 11:15-12:20 | Multiple Myeloma Communications II |
| Moderators: Mohamad Mohty, France; María-Victoria Mateos, Spain; Arnon Nagler, Israel | |
| 11:15-11:25 | Isatuximab in Combination with Lenalidomide and Dexamethasome (Isa-Rd) in Patients with High-Risk Smoldering Multiple Myeloma (HR-SMM): Phase 3 ITHACA Study Final Safety Run-in (SRI) Results: María-Victoria Mateos, Spain |
| 11:25-11:35 | Safety Results from REALiTEC Cohort 2: A Multi-Country Observational Study of Teclistamab in Relapsed/Refractory Multiple Myeloma in Real World: TBA |
| 11:35-11:45 | BELANTAMAB MAFODOTIN (BELMAF) IN COMBINATION WITH BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (VRD) FOR PATIENTS (PTS) WITH TRANSPLANT-INELIGIBLE (TI) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A FOCUS ON TREATMENT EFFICACY AND MANAGEMENT/RESOLUTION OF OCULAR EVENTS IN THE PHASE 1 DREAMM-9 STUDY: Saad Usmani, USA |
| 11:45-11:55 | COMPARATIVE EFFICACY OF LINVOSELTAMAB VERSUS IDECABTAGENE VICLEUCEL (IDE-CEL) AND CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC): Joshua Richter, USA |
| 11:55-12:05 | PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO ACHIEVED SUSTAINED MINIMAL RESIDUAL DISEASE-NEGATIVITY WITH BELANTAMAB MAFODOTIN (BELAMAF) TREATMENT IN DREAMM-7: María-Victoria Mateos, Spain |
| 12:05-12:20 | Discussion |
| 12:20-12:30 | Conclusion and see you next year! |
